Date: 2014-10-07
Type of information: Nomination
Compound: member of the board of directors
Company: Oncobiologics (USA - NJ)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 7, 2014, Oncobiologics, a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors. Dr. Brady joined Aldeyra as CEO, President and Director in 2011, where he was instrumental in leading the company through its initial public offering on NASDAQ. Prior to Aldeyra, he was an entrepreneur-in-residence and principal at Domain Associates, where he led institutional financing in numerous biotechnology companies from 2004 to 2013. Prior to joining Domain, Dr. Brady was a co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma). Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School, and an A.B. from Dartmouth College.
Financial terms:
Latest news:
Is general: Yes
